View in EDS HTML Full Text PDF Full Text

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
Authors: McQuilten ZK; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.; Department of Haematology, Monash Health, Melbourne, Australia., Busija L; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia., Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Stanworth S; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Clinical Department, NHS Blood and Transplant, Oxford, UK.; Radcliffe Department of Medicine, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, UK., Wood EM; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.; Department of Haematology, Monash Health, Melbourne, Australia., Kenealy M; Cabrini Health, Melbourne, Australia.; Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia., Weinkove R; Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealand.; Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.; Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
Corporate Authors: Australasian Leukaemia and Lymphoma Group (ALLG)
Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 Mar; Vol. 63 (3), pp. 676-683. Date of Electronic Publication: 2021 Dec 17.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34915809
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22McQuilten+ZK%22">McQuilten ZK</searchLink>; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.; Department of Haematology, Monash Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Busija+L%22">Busija L</searchLink>; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Seymour+JF%22">Seymour JF</searchLink>; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Stanworth+S%22">Stanworth S</searchLink>; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Clinical Department, NHS Blood and Transplant, Oxford, UK.; Radcliffe Department of Medicine, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Wood+EM%22">Wood EM</searchLink>; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.; Department of Haematology, Monash Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Kenealy+M%22">Kenealy M</searchLink>; Cabrini Health, Melbourne, Australia.; Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Weinkove+R%22">Weinkove R</searchLink>; Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealand.; Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.; Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Australasian+Leukaemia+and+Lymphoma+Group+%28ALLG%29%22">Australasian Leukaemia and Lymphoma Group (ALLG)</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2022 Mar; Vol. 63 (3), pp. 676-683. <i>Date of Electronic Publication: </i>2021 Dec 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34915809
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2021.2012664
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 676
    Titles:
      – TitleFull: Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: McQuilten ZK
      – PersonEntity:
          Name:
            NameFull: Busija L
      – PersonEntity:
          Name:
            NameFull: Seymour JF
      – PersonEntity:
          Name:
            NameFull: Stanworth S
      – PersonEntity:
          Name:
            NameFull: Wood EM
      – PersonEntity:
          Name:
            NameFull: Kenealy M
      – PersonEntity:
          Name:
            NameFull: Weinkove R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2022 Mar
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 63
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1